| 2026-08-07 | Press release | Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-29 | Press release | Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults |
| 2026-07-28 | Press release | Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates |
| 2026-07-17 | Press release | Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congr |
| 2026-07-13 | Press release | Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in |
| 2026-07-08 | Press release | Incyte to Report Second Quarter Financial Results |
| 2026-07-06 | Press release | Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematol |
| 2026-06-26 | Press release | Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopi |
| 2026-06-19 | Press release | Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults w |
| 2026-06-14 | Press release | Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibro |
| 2026-06-13 | Press release | Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 20 |
| 2026-06-13 | Press release | Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molec |
| 2026-06-08 | Press release | Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio |
| 2026-06-04 | Press release | Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans P |
| 2026-05-30 | Press release | Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression- |
| 2026-05-26 | Press release | Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference |
| 2026-05-20 | Press release | Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery |
| 2026-05-19 | Press release | Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Developm |
| 2026-05-12 | Press release | Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Cong |
| 2026-05-07 | Press release | Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Mode |
| 2026-05-06 | Press release | Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-01 | Press release | Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, P |
| 2026-04-29 | Press release | Incyte to Present at Upcoming Investor Conferences |
| Press release | Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates |
| 2026-04-28 | Press release | Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer |
| 2026-04-09 | Press release | Incyte to Report First Quarter Financial Results |
| 2026-03-28 | Press release | Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 Americ |
| 2026-03-25 | Press release | Incyte Announces Executive Leadership Appointments |
| 2026-03-20 | Press release | Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual |
| 2026-03-06 | Press release | Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squa |
| 2026-02-17 | Press release | Incyte to Present at Upcoming Investor Conferences |
| 2026-02-10 | Press release | Incyte Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-01-30 | Press release | Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carc |
| 2026-01-27 | Press release | Incyte to Report Fourth Quarter and Year-End 2025 Financial Results |
| 2026-01-12 | Presentation | JP Morgan Healthcare Conference Presentation |
| 2026-01-05 | Press release | Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatmen |
| 2025-12-07 | Presentation | ASH 2025 - Incyte Investor Event |
| 2025-10-28 | Press release | Q3 |
| 2025-07-29 | Press release | Q2 |
| 2025-06-15 | Presentation | MPN Data Highlights from EHA 2025 |